Followers | 38 |
Posts | 5652 |
Boards Moderated | 0 |
Alias Born | 11/09/2003 |
Tuesday, September 05, 2017 11:18:15 AM
PR NewswireSeptember 5, 2017
Company Begins New Fiscal Year with $53.6 Million in Cash
Clinical Progress Highlighted by Initiation of Pivotal Study for Pracinostat, Emerging Response and Safety Data for ME-401
Management Team to Host Conference Call Today at 9:00 a.m. Eastern Time
SAN DIEGO, Sept. 5, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its fiscal year ended June 30, 2017.
"We begin our new fiscal year with strong momentum, a maturing pipeline of clinical-stage oncology drug candidates and a healthy cash balance," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "We have made significant strides in the clinic over the past several months, underscored by the dosing of the first patients in the pivotal Phase 3 study of pracinostat in AML, as well as in the Phase 2 dose-optimization study of pracinostat in MDS. Meanwhile, we are very excited by the response and safety data that are emerging from the open-label study of our PI3K delta inhibitor ME-401. This program continues to exceed our high expectations and we look forward to the opportunity to present more data at an upcoming scientific meeting."
Financial Highlights
• As of June 30, 2017, MEI Pharma had $53.6 million in cash, cash equivalents and short-term investments, with no outstanding debt. The Company believes its cash position will be sufficient to fund operations into calendar year 2019.
• Cash expenditures were $16.5 million for the year ended June 30, 2017, compared to $17.9 million for 2016. Cash expenditures were $3.1 million for the fourth quarter ended June 30, 2017, compared to $3.5 million for the same period in 2016.
• Research and development expenses were $7.2 million for the year ended June 30, 2017, compared to $13.4 million for 2016. The decrease was primarily due to a reduction in expenses related to pracinostat pursuant to the Helsinn License Agreement.
• General and administrative expenses were $8.6 million for the year ended June 30, 2017, compared to $7.6 million for 2016. The increase was primarily due to professional service costs.
• Revenues were $23.2 million for the year ended June 30, 2017, related to the Helsinn License Agreement. During the year ended June 30, 2017, the cost of research and development revenue was $5.0 million. Cost of research and development revenue is comprised primarily of reimbursable third-party pass-through costs.
• Net income was $2.7 million, or $0.07 per share, for the fiscal year ended June 30, 2017, compared to a net loss of $20.9 million, or $0.61 per share for 2016.
Recent Clinical Milestones
• First patient dosed in pivotal Phase 3 study of pracinostat in AML. In July 2017, the first patient was dosed in a pivotal Phase 3 study of the investigational drug candidate pracinostat in combination with azacitidine in adults with newly diagnosed acute myeloid leukemia (AML) who are unfit to receive intensive induction chemotherapy. The randomized, double-blind, placebo-controlled study will enroll approximately 500 eligible patients worldwide. Helsinn Healthcare, SA, a Swiss pharmaceutical company, has an exclusive license to develop, manufacture and commercialize pracinostat (Helsinn License Agreement), and is responsible for the conduct and funding of this Phase 3 study.
• First patient dosed in Phase 2 dose-optimization study of pracinostat in MDS. In June 2017, the first patient was dosed in a Phase 2 dose-optimization study of pracinostat in combination with azacitidine in patients with high and very high risk myelodysplastic syndrome (MDS) who are previously untreated with hypomethylating agents. The two-stage study will be conducted at approximately 25 sites and is expected to enroll up to 120 patients. Data from the first stage is expected in the first quarter of 2018. MEI Pharma is responsible for the conduct of this Phase 2 study, the cost of which will be shared by Helsinn. Helsinn will be responsible for funding any further studies.
• Genetic mutation data from Phase 2 study of pracinostat in AML. In June 2017, results from a mutational analysis of patients in the Phase 2 study of pracinostat and azacitidine in AML were presented at the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings. The findings showed: 1) a statistically significant correlation between genetic mutations in the DNA methylation pathway and clinical response; 2) the mutation profile in the Phase 2 study was representative not only of the larger population of older AML patients, but common in MDS patients as well; and 3) that median overall survival was roughly equivalent in patients with mutations typically associated with de novo AML (18.1 months) and secondary AML (17.7 months). In addition, longitudinal sequencing analyses showed that continued treatment with pracinostat and azacitidine increases the rate of minimal residual disease (MRD) clearance.
• Emerging data from Phase 1b study of ME-401 in CLL and follicular lymphoma.In May 2017, an independent safety review committee completed its review of the first cohort of six evaluable patients in an ongoing Phase 1b dose-escalation study of the Company's oral PI3K delta inhibitor ME-401 in relapsed/refractory chronic lymphocytic leukemia (CLL) and follicular lymphoma. The safety review committee found no dose-limiting toxicities, declared a minimum biologically effective dose (response rate > 50%) at the starting dose of 60 mg and recommended escalation to a 120 mg dose cohort. To date, the study has enrolled a total of 18 patients who are evaluable for safety, four of whom are still too early for a response assessment. The 18 patients have been on study for a median of approximately three months (range, 1-10 months) and no patients have discontinued due to adverse events or disease progression.
Conference Call and Webcast
MEI Pharma's management team will host a conference call with simultaneous webcast today, September 5, 2017, at 9:00 a.m. Eastern time to discuss the Company's fiscal year 2017 results. To access the live call, please dial 888-357-5399 (toll-free) or 440-996-5704 (international), conference ID 71495273. The conference call will also be webcast live and can be accessed at www.meipharma.com. A replay of the webcast will be available approximately one hour after the conclusion of the call.
Bladerunner
Recent MEIP News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/19/2024 09:20:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 09:05:07 PM
- MEI Pharma Reports Fiscal Year End 2024 Cash Position • Business Wire • 09/19/2024 08:01:00 PM
- MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives • Business Wire • 08/12/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:05:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 09:25:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 08:06:33 PM
- MEI Pharma to Consider Strategic Alternatives • Business Wire • 07/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 05:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:02:15 PM
- MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 05/09/2024 08:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:00:47 PM
- MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 • Business Wire • 04/11/2024 12:02:00 PM
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients • Business Wire • 04/11/2024 12:00:00 PM
- MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum • Business Wire • 04/10/2024 12:00:00 PM
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia • Business Wire • 03/26/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/29/2024 05:15:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:00:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 10:33:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 10:05:14 PM
- MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 02/13/2024 10:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM